Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2019

Open Access 01-12-2019 | Multiple Sclerosis | Study protocol

Neuropsychological management of multiple sclerosis: evaluation of a supervised and customized cognitive rehabilitation program for self-used at home (SEPIA): protocol for a randomized controlled trial

Authors: Caroline Harand, France Daniel, Audrey Mondou, Damien Chevanne, Christian Creveuil, Gilles Defer

Published in: Trials | Issue 1/2019

Login to get access

Abstract

Background

Cognitive and mood disorders negatively impact daily life in patients with multiple sclerosis (MS). Pharmacological treatments did not demonstrate any effect on cognition compared with cognitive rehabilitation (CR). However, if CR programs offer promising results on cognition, they are less consistent concerning mood and quality of life (QoL). In this context, we designed a randomized controlled trial to evaluate the efficacy of an innovative computerized CR program, conducted at home, on QoL. Secondary objectives will estimate the improvement, or the stabilization over time, of patients’ cognitive performances and their emotional affects.

Methods

Forty MS patients (relapsing-remitting or secondary progressive forms) who have cognitive impairment will be recruited for the trial (called SEPIA-NCT03471338) and randomly assigned to either the experimental group or the control group. Patients randomly assigned in the experimental group will perform a home-based CR program with psychological support during eight consecutive weeks. CR will be based on computerized cognitive exercises from the PRESCO® software developed by HAPPYneuron©. Training sessions (three sessions of 45 min per week) will consist of short exercises evaluating a broad range of cognitive domains and will be personalized for each patient (tracking tool and supervised guidance). The control group, designed to control for non-specific elements of the intervention, will receive only psychological support consisting of various issues related to MS, such as everyday cognitive-related difficulties or management of emotions. QoL, assessed by the MUSIQOL (Multiple Sclerosis International Quality Of Life) questionnaire, will be evaluated three times (at baseline and after 1 week and 25 weeks after home-based intervention) as well as secondary outcomes measuring self-esteem, cognition, depression, anxiety, metacognition, fatigue, and sleep quality. Given the expected MUSIQOL variation, the inclusion of 20 patients per group (alpha risk 5% and power 80%) will be required.

Discussion

Evidence suggests that computerized programs may be a practice option for CR for people with MS, but there is a paucity of studies evaluating QoL. We hope that this innovative program will highlight such benefits over time in patients’ daily life. In the future, such programs will allow a wider range of available therapeutic options for MS patients with cognitive impairment and for practitioners in charge of their care.

Trial registration

Appendix
Available only for authorised users
Literature
1.
2.
3.
4.
Nauta IM, Speckens AEM, Kessels RPC, Geurts JJG, de Groot V, Uitdehaag BMJ, et al. Cognitive rehabilitation and mindfulness in multiple sclerosis (REMIND-MS): a study protocol for a randomised controlled trial. BMC Neurol. 2017;17(1):201. https://​doi.​org/​10.​1186/​s12883-017-0979-y.
5.
Harand C, Defer G. Prise en charge des troubles cognitifs. In: La Sclérose En Plaques - Clinique et Thérapeutique. Elsevier Masson SAS, 65 rue Camille Desmoulins, 92442 Issy-les-Moulineaux, France; 2017. p. 197–204.
6.
7.
Shao Y, Mang J, Li P, Wang J, Deng T, Xu Z. Computer-based cognitive programs for improvement of memory, processing speed and executive function during age-related cognitive decline: a meta-analysis. PLoS One. 2015;10(6):e0130831.
8.
Messinis L, Papathanasopoulos P, Kosmidis MH, Nasios G, Kambanaros M. Neuropsychological features of multiple sclerosis: impact and rehabilitation. Behav Neurol. 2018;2018:4831647.
9.
das Nair R, Martin K-J, Lincoln NB. Memory rehabilitation for people with multiple sclerosis. Cochrane Database Syst Rev. 2016;3:CD008754.
10.
Rosti-Otajärvi EM, Hämäläinen PI. Neuropsychological rehabilitation for multiple sclerosis. Cochrane Database Syst Rev. 2014;(2):CD009131.
11.
Mitolo M, Venneri A, Wilkinson ID, Sharrack B. Cognitive rehabilitation in multiple sclerosis: a systematic review. J Neurol Sci. 2015;354(1-2):1–9.
12.
Hämäläinen P, Rosti-Otajärvi E. Cognitive impairment in MS: rehabilitation approaches. Acta Neurol Scand. 2016;134(Suppl 200):8–13.
13.
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302.
14.
Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–86.
15.
Dujardin K, Sockeel P, Cabaret M, De Sèze J, Vermersch P. BCcogSEP: a French test battery evaluating cognitive functions in multiple sclerosis. Rev Neurol. (Paris). 2004;160(1):51–62.
16.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders DSM-5. 5th ed. Arlington: American Psychiatric Publishing; 2013.
17.
Simeoni M, Auquier P, Fernandez O, Flachenecker P, Stecchi S, Constantinescu C, et al. MusiQol study group. Mult Scler. 2008;14(2):219–30.
18.
Baumstarck-Barrau K, Pelletier J, Simeoni M-C, Auquier P. Validation française du Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL). Rev Neurol. (Paris). 2011;167:511–21.CrossRef
19.
Baumstarck K, Boucekine M, Boyer L, Aghababian V, Parola N, Reuter F, et al. Quantification of relevance of quality of life assessment for patients with cognitive impairment: the suitability indices. BMC Neurol. 2014;14:78.
20.
Coopersmith S. The antecedents of self-esteem. San Francisco: W.H. Freeman & Co; 1967.
21.
Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry J Ment Sci. 1979;134:382–9.CrossRef
22.
Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50–5.
23.
Wells A, Cartwright-Hatton S. A short form of the metacognitions questionnaire: properties of the MCQ-30. Behav Res Ther. 2004;42(4):385–96.
24.
Debouverie M, Pittion-Vouyovitch S, Louis S, Guillemin F. Validity of a French version of the fatigue impact scale in multiple sclerosis. Mult Scler. 2007;13(8):1026–32.
25.
Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213.
26.
Benedict RH, Amato MP, Boringa J, Brochet B, Foley F, Fredrikson S, et al. Brief International Cognitive Assessment for MS (BICAMS): international standards for validation. BMC Neurol. 2012;12:55.
27.
Benedict RHB. Brief visuospatial memory test revised: professional manual. Lutz: PAR, Inc; 1997.
28.
Delis K, Kramer J, Kaplan E, Ober BA. California verbal learning test (CVLT) manual. San Antonio: Psychological Corporation; 1987.
29.
Smith A. Symbol digit modalities test. Los Angeles: Western Psychological Services; 1982.
30.
Rao SM and the cognitive function study group of the national multiple sclerosis society. A manual for the brief, repeatable battery of neuropsychological tests in multiple sclerosis. Milwaukee: Medical college of Wisconsin; 1991.
31.
Martin R. Test des commissions. 2nd ed. Bruxelles: Editest; 1972.
32.
Klinger E, Chemin I, Lebreton S, Marié RM. A virtual supermarket to assess cognitive planning. Cyberpsychological Behav. 2004;7:292–3.
33.
34.
Planche V, Moisset X, Morello R, Dumont E, Gibelin M, Charré-Morin J, et al. Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab: a 3-year follow-up multicentric study. J Neurol Sci. 2017;382:148–54.
35.
Borm GF, Fransen J, Lemmens WA. A simple sample size formula for analysis of covariance in randomized clinical trials. J Clin Epidemiol. 2007;60(12):1234–8.
36.
Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869.
37.
ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group. Stat Med. 1999;18(15):1905–42.
38.
Porta N, Bonet C, Cobo E. Discordance between reported intention-to-treat and per protocol analyses. J Clin Epidemiol. 2007;60(7):663–9.
39.
IBM Corp, Released. IBM SPSS statistics for Windows, version 22.0. Armonk: IBM Corp; 2013.
40.
Amato MP, Langdon D, Montalban X, Benedict RH, DeLuca J, Krupp LB, et al. Treatment of cognitive impairment in multiple sclerosis: position paper. J Neurol. 2013;260(6):1452–68.
41.
Dardiotis E, Nousia A, Siokas V, Tsouris Z, Andravizou A, Mentis AA, et al. Efficacy of computer-based cognitive training in neuropsychological performance of patients with multiple sclerosis: a systematic review and meta-analysis. Mult Scler Relat Disord. 2018;20:58–66.
42.
Stuifbergen AK, Becker H, Perez F, Morrison J, Brown A, Kullberg V, et al. Computer-assisted cognitive rehabilitation in persons with multiple sclerosis: Results of a multi-site randomized controlled trial with six month follow-up. Disabil Health J. 2018;11(3):427–434.
Metadata
Title
Neuropsychological management of multiple sclerosis: evaluation of a supervised and customized cognitive rehabilitation program for self-used at home (SEPIA): protocol for a randomized controlled trial
Authors
Caroline Harand
France Daniel
Audrey Mondou
Damien Chevanne
Christian Creveuil
Gilles Defer
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Trials / Issue 1/2019
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-019-3715-7

Other articles of this Issue 1/2019

Trials 1/2019 Go to the issue

Correction

Correction to: Gabapentin as add-on to morphine for severe neuropathic or mixed pain in children from age 3 months to 18 years - evaluation of the safety, pharmacokinetics, and efficacy of a new gabapentin liquid formulation: study protocol for a randomized controlled trial

Study protocol

The effect of daily consumption of different doses of fortified Lavash bread versus plain bread on serum vitamin-D status, body composition, metabolic and inflammatory biomarkers, and gut microbiota in apparently healthy adult: study protocol of a randomized clinical trial

Study protocol

Nebulized versus intravenous morphine titration for the initial treatment of severe acute pain in the emergency department: study protocol for a multicenter, prospective randomized and controlled trial, CLIN-AEROMORPH

Study protocol

Long-term effects of motherfit group therapy in pre-(MOTHERFIT1) and post-partum women (MOTHERFIT2) with stress urinary incontinence compared to care-as-usual: study protocol of two multi-centred, randomised controlled trials

Update

Efficacy of electro-acupuncture and manual acupuncture versus sham acupuncture for knee osteoarthritis: statistical analysis plan for a randomized controlled trial

Commentary

Trial management: we need a cadre of high-class triallists to deliver the answers that patients need